AAPL315.62-0.60 (-0.19%) ▼|ABBV250.37+1.59 (+0.64%) ▲|ABT105.40-0.12 (-0.11%) ▼|ACN177.31-1.72 (-0.96%) ▼|ADBE255.49-1.78 (-0.69%) ▼|AMAT467.78-5.01 (-1.06%) ▼|AMD519.22+13.48 (+2.67%) ▲|AMGN392.11-1.07 (-0.27%) ▼|AMT175.37-0.37 (-0.21%) ▼|AMZN252.15-4.83 (-1.88%) ▼|AVGO363.76-4.81 (-1.30%) ▼|AXP322.54-3.57 (-1.09%) ▼|BA208.00-2.73 (-1.30%) ▼|BAC62.90+0.51 (+0.81%) ▲|BKNG173.08-7.23 (-4.01%) ▼|BLK1,075.34-20.04 (-1.83%) ▼|BMY64.31-0.39 (-0.60%) ▼|BNY163.26+0.41 (+0.25%) ▲|BRK-B507.31+1.48 (+0.29%) ▲|C138.43+1.69 (+1.23%) ▲|CAT818.05-4.43 (-0.54%) ▼|CL88.02-0.39 (-0.44%) ▼|CMCSA24.56-1.77 (-6.72%) ▼|COF212.55-1.42 (-0.66%) ▼|COP137.24+2.20 (+1.63%) ▲|COST901.49-8.69 (-0.95%) ▼|CRM244.28-4.85 (-1.94%) ▼|CSCO109.28+0.11 (+0.10%) ▲|CVS95.82-0.25 (-0.26%) ▼|CVX214.01+4.21 (+2.01%) ▲|DE677.21-3.53 (-0.52%) ▼|DHR205.08-0.15 (-0.07%) ▼|DIS104.43-0.63 (-0.60%) ▼|DUK120.32-0.92 (-0.76%) ▼|EMR151.08-1.07 (-0.70%) ▼|FDX310.14-3.99 (-1.27%) ▼|GD352.72-3.87 (-1.08%) ▼|GE326.49-8.42 (-2.52%) ▼|GEV953.40-17.91 (-1.84%) ▼|GILD145.74-0.90 (-0.61%) ▼|GM84.75-1.04 (-1.21%) ▼|GOOG328.54-6.85 (-2.04%) ▼|GOOGL330.99-7.38 (-2.18%) ▼|GS1,031.66-4.87 (-0.47%) ▼|HD311.17-2.53 (-0.81%) ▼|HON205.26-2.98 (-1.43%) ▼|IBM239.46+7.37 (+3.18%) ▲|INTC106.23+1.76 (+1.68%) ▲|INTU314.34-4.59 (-1.44%) ▼|ISRG352.63+2.47 (+0.71%) ▲|JNJ267.95-1.17 (-0.43%) ▼|JPM355.39+1.88 (+0.53%) ▲|KO87.79-0.58 (-0.65%) ▼|LIN466.02-2.36 (-0.50%) ▼|LLY1,125.26+1.35 (+0.12%) ▲|LMT526.31-9.84 (-1.84%) ▼|LOW198.71-2.09 (-1.04%) ▼|LRCX314.93-5.50 (-1.71%) ▼|MA569.83-1.06 (-0.19%) ▼|MCD254.55-1.26 (-0.49%) ▼|MDLZ62.28+0.65 (+1.05%) ▲|MDT92.07-0.32 (-0.35%) ▼|META655.08+41.60 (+6.78%) ▲|MMM164.39-3.13 (-1.87%) ▼|MO67.83-0.34 (-0.50%) ▼|MRK147.81-0.65 (-0.44%) ▼|MS215.92-0.32 (-0.15%) ▼|MSFT491.59-2.37 (-0.48%) ▼|MU1,029.05+28.79 (+2.88%) ▲|NEE83.08-0.76 (-0.90%) ▼|NFLX76.13-0.64 (-0.83%) ▼|NKE37.26-0.85 (-2.22%) ▼|NOW131.85-2.36 (-1.76%) ▼|NVDA223.79-1.94 (-0.86%) ▼|ORCL162.64+0.12 (+0.07%) ▲|PEP137.14-1.31 (-0.94%) ▼|PFE27.81+0.02 (+0.07%) ▲|PG142.74-2.84 (-1.95%) ▼|PLTR170.33+0.03 (+0.01%) ▲|PM185.58+0.85 (+0.46%) ▲|QCOM175.42+1.33 (+0.76%) ▲|RTX198.14-0.67 (-0.34%) ▼|SBUX100.60-1.41 (-1.38%) ▼|SCHW106.74-0.14 (-0.13%) ▼|SO88.46-0.54 (-0.60%) ▼|SPG205.58-4.06 (-1.93%) ▼|T25.17-0.43 (-1.68%) ▼|TMO608.81+5.79 (+0.96%) ▲|TMUS177.96-3.73 (-2.05%) ▼|TSLA369.13+0.97 (+0.26%) ▲|TXN260.83+1.91 (+0.74%) ▲|UBER71.30-1.84 (-2.51%) ▼|UNH392.25-8.59 (-2.14%) ▼|UNP285.01-3.44 (-1.19%) ▼|UPS99.44-1.04 (-1.04%) ▼|USB62.26-0.24 (-0.38%) ▼|V368.61-0.03 (-0.01%) ▼|VZ49.76-0.65 (-1.29%) ▼|WFC89.77+1.81 (+2.05%) ▲|WMT105.91-0.14 (-0.13%) ▼|XOM164.05+3.39 (+2.11%) ▲|AAPL315.62-0.60 (-0.19%) ▼|ABBV250.37+1.59 (+0.64%) ▲|ABT105.40-0.12 (-0.11%) ▼|ACN177.31-1.72 (-0.96%) ▼|ADBE255.49-1.78 (-0.69%) ▼|AMAT467.78-5.01 (-1.06%) ▼|AMD519.22+13.48 (+2.67%) ▲|AMGN392.11-1.07 (-0.27%) ▼|AMT175.37-0.37 (-0.21%) ▼|AMZN252.15-4.83 (-1.88%) ▼|AVGO363.76-4.81 (-1.30%) ▼|AXP322.54-3.57 (-1.09%) ▼|BA208.00-2.73 (-1.30%) ▼|BAC62.90+0.51 (+0.81%) ▲|BKNG173.08-7.23 (-4.01%) ▼|BLK1,075.34-20.04 (-1.83%) ▼|BMY64.31-0.39 (-0.60%) ▼|BNY163.26+0.41 (+0.25%) ▲|BRK-B507.31+1.48 (+0.29%) ▲|C138.43+1.69 (+1.23%) ▲|CAT818.05-4.43 (-0.54%) ▼|CL88.02-0.39 (-0.44%) ▼|CMCSA24.56-1.77 (-6.72%) ▼|COF212.55-1.42 (-0.66%) ▼|COP137.24+2.20 (+1.63%) ▲|COST901.49-8.69 (-0.95%) ▼|CRM244.28-4.85 (-1.94%) ▼|CSCO109.28+0.11 (+0.10%) ▲|CVS95.82-0.25 (-0.26%) ▼|CVX214.01+4.21 (+2.01%) ▲|DE677.21-3.53 (-0.52%) ▼|DHR205.08-0.15 (-0.07%) ▼|DIS104.43-0.63 (-0.60%) ▼|DUK120.32-0.92 (-0.76%) ▼|EMR151.08-1.07 (-0.70%) ▼|FDX310.14-3.99 (-1.27%) ▼|GD352.72-3.87 (-1.08%) ▼|GE326.49-8.42 (-2.52%) ▼|GEV953.40-17.91 (-1.84%) ▼|GILD145.74-0.90 (-0.61%) ▼|GM84.75-1.04 (-1.21%) ▼|GOOG328.54-6.85 (-2.04%) ▼|GOOGL330.99-7.38 (-2.18%) ▼|GS1,031.66-4.87 (-0.47%) ▼|HD311.17-2.53 (-0.81%) ▼|HON205.26-2.98 (-1.43%) ▼|IBM239.46+7.37 (+3.18%) ▲|INTC106.23+1.76 (+1.68%) ▲|INTU314.34-4.59 (-1.44%) ▼|ISRG352.63+2.47 (+0.71%) ▲|JNJ267.95-1.17 (-0.43%) ▼|JPM355.39+1.88 (+0.53%) ▲|KO87.79-0.58 (-0.65%) ▼|LIN466.02-2.36 (-0.50%) ▼|LLY1,125.26+1.35 (+0.12%) ▲|LMT526.31-9.84 (-1.84%) ▼|LOW198.71-2.09 (-1.04%) ▼|LRCX314.93-5.50 (-1.71%) ▼|MA569.83-1.06 (-0.19%) ▼|MCD254.55-1.26 (-0.49%) ▼|MDLZ62.28+0.65 (+1.05%) ▲|MDT92.07-0.32 (-0.35%) ▼|META655.08+41.60 (+6.78%) ▲|MMM164.39-3.13 (-1.87%) ▼|MO67.83-0.34 (-0.50%) ▼|MRK147.81-0.65 (-0.44%) ▼|MS215.92-0.32 (-0.15%) ▼|MSFT491.59-2.37 (-0.48%) ▼|MU1,029.05+28.79 (+2.88%) ▲|NEE83.08-0.76 (-0.90%) ▼|NFLX76.13-0.64 (-0.83%) ▼|NKE37.26-0.85 (-2.22%) ▼|NOW131.85-2.36 (-1.76%) ▼|NVDA223.79-1.94 (-0.86%) ▼|ORCL162.64+0.12 (+0.07%) ▲|PEP137.14-1.31 (-0.94%) ▼|PFE27.81+0.02 (+0.07%) ▲|PG142.74-2.84 (-1.95%) ▼|PLTR170.33+0.03 (+0.01%) ▲|PM185.58+0.85 (+0.46%) ▲|QCOM175.42+1.33 (+0.76%) ▲|RTX198.14-0.67 (-0.34%) ▼|SBUX100.60-1.41 (-1.38%) ▼|SCHW106.74-0.14 (-0.13%) ▼|SO88.46-0.54 (-0.60%) ▼|SPG205.58-4.06 (-1.93%) ▼|T25.17-0.43 (-1.68%) ▼|TMO608.81+5.79 (+0.96%) ▲|TMUS177.96-3.73 (-2.05%) ▼|TSLA369.13+0.97 (+0.26%) ▲|TXN260.83+1.91 (+0.74%) ▲|UBER71.30-1.84 (-2.51%) ▼|UNH392.25-8.59 (-2.14%) ▼|UNP285.01-3.44 (-1.19%) ▼|UPS99.44-1.04 (-1.04%) ▼|USB62.26-0.24 (-0.38%) ▼|V368.61-0.03 (-0.01%) ▼|VZ49.76-0.65 (-1.29%) ▼|WFC89.77+1.81 (+2.05%) ▲|WMT105.91-0.14 (-0.13%) ▼|XOM164.05+3.39 (+2.11%) ▲|
28.6 C
New York
Wednesday, September 9, 2026

Tag: collaborations

newssourceFORcompanyinformationcontent1releasesmarket

Immunocore to report second quarter 2025 financial results and host call on August 7, 2025

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, July 31, 2025) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that it will report second quarter financial results, before the US markets open on Thursday, August 7, 2025.

VedTechBio Unveils Next-Gen Drug Discovery AI; Partners with AlphaMeld in Multi-Therapy Collaboration

VedTechBio enhances RxAgentAI platform; teams with US-based AlphaMeld to cut drug discovery time and co-develop therapies for rare and metabolic diseases.

THR-β Agonist Market on the Rise: Insights and Projections Upto 2034 | DelveInsight

The THR‑β agonist market is witnessing rapid growth, fueled by the increasing global prevalence of metabolic disorders such as MASH and rare genetic conditions...

THR-β Agonist Market on the Rise: Insights and Projections Upto 2034 | DelveInsight

The THR‑β agonist market is witnessing rapid growth, fueled by the increasing global prevalence of metabolic disorders such as MASH and rare genetic conditions...

Two-Year Real-World Study of LEQEMBI® in the United States Presented at Alzheimer’s Association International Conference (AAIC) 2025

TOKYO and CAMBRIDGE, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the two-year real-world study in the U.S of lecanemab (generic name, product name: LEQEBMI®), an anti-Aβ protofibril* antibody, was presented at the Alzheimer's Association International Conference (AAIC) 2025, held in Toronto, Canada and virtually. Only lecanemab fights AD in two ways – targeting both amyloid plaque and protofibrils*, which can impact tau downstream.

OpenText and TELUS partner to deliver Canadian sovereign AI-powered solutions for government and business

WATERLOO, ON, July 30, 2025 /PRNewswire/ -- OpenText™ (NASDAQ: OTEX), (TSX: OTEX), the leading information management company, and TELUS, a world-leading communications technology company, today...

RBL Launches TruPartner Score™: Raising the Bar for Authenticity in Tech Partner Marketing

AUSTIN, Texas, July 30, 2025 (GLOBE NEWSWIRE) -- Round Barn Labs (RBL), a leader in affiliate and influencer marketing for tech brands like Future Fitness, Atlassian, Grammarly, Wyze, Remote, and Meta Quest, unveils TruPartner Score™—a proprietary algorithm that empowers brands to build high-performing, trusted partnerships.

The World’s First “Superfluidized Inorganic Solid-State Electrolyte” Paves the Way for Full-Scale Commercialization of Next-Generation Solid-State Lithium Batteries

ProLogium today unveiled its groundbreaking fourth-generation innovation—the Superfluidized Inorganic Solid-State Electrolyte

Access Unparalleled: Premier Hosted Buyers Converge on Global Beverage & Tea Trends 2025

SHANGHAI, July 30, 2025 /PRNewswire/ -- The 28th edition of FHC Shanghai Global Food Trade Show will return to the Shanghai New International Expo Centre...

Dr. Falk Pharma and Allianthera (Suzhou) Biopharmaceuticals Forge Strategic Partnership for Novel AhR Agonist Development

Freiburg (Germany), Suzhou (China) and Boston (USA), July 30, 2025: 

Photocure ASA: Results for the second quarter of 2025

OSLO, Norway, July 30, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO) today reported Hexvix®/Cysview® revenues of NOK 135.6 million in the second quarter of 2025...

Photocure ASA: Results for the second quarter of 2025

OSLO, Norway, July 30, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO) today reported Hexvix®/Cysview® revenues of NOK 135.6 million in the second quarter of 2025...

Meet the Finalists: TWOPAGES X Design Contest Public Vote Now Live

A 10th Anniversary Design Tribute, TWOPAGES Ushers in a New Chapter of Global Co-Creation 
A 10th Anniversary Design Tribute, TWOPAGES Ushers in a New Chapter of Global Co-Creation

Harbour BioMed to Present Phase II Data of HBM4003 and Tislelizumab Combination in MSS Metastatic Colorectal Cancer at ESMO 2025

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 29, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company focused on the discovery and development...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsCollaborations

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers